KMKennedy Mwacalimba

Kennedy Mwacalimba

*This is an algorithmically generated author record based on publicly available information.

Kennedy Mwacalimba has a total of 55 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Treatment of heartworm (Dirofilaria immitis) disease in dogs in the USA: general findings and cost of disease

    by Kennedy Mwacalimba, Briana Ferguson, Christopher Brennan, Barbara Poulsen Nautrup, Jennifer Little, Kate Stiefelmeyer, Marina Moldavchuk, Ashley Mosko

    Background: Heartworm (HW) disease is caused by the adult worms of Dirofilaria immitis. Treatment of HW disease is costly and often challenging. Therefore, the mainstay of HW disease management is to prevent the development of adult worms. The objective of this retrospective study was to use a transaction database to collect information and cost estimates on the prevention and treatment of canine HW disease in the USA. Methods: Anonymized transaction data from clinics throughout the USA were used. For the HW disease treatment group (TG) dogs were identified that had a transaction record for adulticidal therapy using melarsomine between August 2022 and July 2023. These dogs were tracked up to 95 days before the first melarsomine treatment for transactions given current American Heartworm Society (AHS) guidelines for the treatment of HW disease. Clinics with records of at least one dog with HW treatment were included. End of the tracking period was 5 days after the last melarsomine injection for the cost evaluation and 12-months for the evaluation of mortality. Included clinics were searched for dogs in the preventive group (PG), i.e., dogs that had a HW test between August 2022 and July 2023, followed by transaction of at least 8.9 HW preventive medication doses over the total observation period of 12 months, starting with the first transaction of HW preventive medication. Results: A total of 2425 dogs were included in the TG and 235,188 dogs qualified for the PG. The adherence to AHS guidelines was low in our study, with stipulated medications and treatments missing in many dogs. Total costs for an average dog with HW disease were calculated at $1457, not considering indirect or intangible costs. Costs of HW preventive medication in year-round purchase compliant dogs were estimated at $182.90. Dogs up to 9 years of age that were treated for HW disease had a significantly higher risk of mortality than dogs in the PG ( p < 0.05). Conclusions: Costs of HW disease treatment are substantial, not considering the intangible effects on the animal and dog owner. The high costs and potential burden of disease underscore the benefit of year-round heartworm disease prevention.

  • Open Access

    A Discrete Choice Experiment to Assess Cat Owners’ Preferences for Topical Antiparasitics and the Comparative Ease of Use of a Combined Selamectin and Sarolaner Formulation: An International Survey

    by Constantina N. Tsokana, George Valiakos, Kennedy Mwacalimba, Danielle Riley, Ashley Enstone, Robin Wyn, Tom Metcalf, Emily Melchior, Eleni Pavlidou, Andrea Wright

    Cat owners are involved in their cats’ healthcare, including the prevention of parasitic diseases. However, a comprehensive understanding of their preferences for feline antiparasitics is lacking. This study addresses this gap through a multifaceted methodology comprising three phases. In Phase 1, the physical properties and usability aspects of seven topical antiparasitic formulations were assessed. Within Phase 2, an ease-of-use study was conducted to evaluate the cat owners’ application experience with deidentified products representing three topical antiparasitics. Phase 3 included the identification and validation of product attributes most valued by pet owners through interviews with cat owners and veterinary experts. The product attributes identified informed the subsequent quantitative discrete choice experiment (DCE), which involved 1040 cat owners from different countries (Australia/New Zealand, Canada, Greece/Spain, and the UK) and aimed to analyze their preferences based on choices among product profiles mirroring four topical antiparasitics: selamectin–sarolaner, moxidectin–fluralaner, moxidectin–imidacloprid, and eprinomectin–esafoxolaner–praziquantel. Phase 1 showed that the selamectin–sarolaner formulation exhibits minimal odor, less stickiness, and less drying time. The ease-of-use study (Phase 2) showed that the blinded product representing the selamectin–sarolaner formulation was characterized by seamless application, rapid dispensing, and a sense of control during application. The quantitative DCE study (Phase 3) indicated a preference for the product profile mirroring the selamectin–sarolaner formulation among a global sample of cat owners. Demographic characteristics such as gender, age, and insurance status influenced their preferences. Key predictors for preferring the selamectin–sarolaner formulation over at least one comparator treatment included the ability to confirm successful administration, age restrictions, ease of application, and the time before the cat could sit on furniture following administration. These findings suggest that cat owners prioritize ease of use, safety, and overall user experience, providing valuable guidance for veterinary practitioners to make informed treatment recommendations.


  • Open Access

    A Discrete Choice Experiment to Assess Cat Owners' Preferences for Topical Antiparasitics and the Comparative Ease-of-Use of a Combined Selamectin and Sarolaner Formulation: An International Survey

    by Constantina N Tsokana, George Valiakos, Kennedy Mwacalimba, Danielle Riley, Ashley Enstone, Robin Wyn, Tom Metcalf, Emily Melchior, Eleni Pavlidou, Andrea Wright

    Cat owners are involved in their cats’ healthcare, including the prevention of parasitic diseases. However, a comprehensive understanding of their preferences for feline antiparasitics is lacking. This study addresses this gap through a multifaceted methodology comprising three phases. In Phase 1, the physical properties and usability aspects of seven topical antiparasitic formulations were assessed. Within Phase 2, an ease-of-use study was conducted to evaluate the cat owners’ application experience with deidentified products representing three topical antiparasitics. Phase 3 included the identification and validation of product attributes most valued by pet owners through interviews with cat owners and veterinary experts. The product attributes identified informed the subsequent quantitative discrete choice experiment (DCE), which involved 1,040 cat owners from different countries and aimed to analyze their preferences based on choices among product profiles mirroring four topical antiparasitics: selamectin-sarolaner, moxidectin-fluralaner, moxidectin-imidacloprid, and eprinomectin-esafoxolaner-praziquantel. Phase 1 showed that the selamectin-sarolaner formulation exhibits minimal odor, less stickiness, and less drying time. The ease-of-use study (Phase 2) showed that the blinded product representing the selamectin-sarolaner formulation was characterized by seamless application, rapid dispensing, and a sense of control during application. The quantitative DCE study (Phase 3) indicated a preference for the product profile mirroring the selamectin-sarolaner formulation among a global sample of cat owners. Demographic characteristics such as gender, age, and insurance status influenced their preferences. Key predictors for preferring the selamectin-sarolaner formulation over at least one comparator treatment included the ability to confirm successful administration, age restrictions, ease of application, and the time before the cat could sit on furniture following administration. These findings suggest that cat owners prioritize ease of use, safety, and overall user experience, providing valuable guidance for veterinary practitioners to make informed treatment recommendations.


  • Top Cited Papers
    Open Access

    Important Diseases of Small Ruminants in Sub-Saharan Africa: A Review with a Focus on Current Strategies for Treatment and Control in Smallholder Systems

    by Peter Kimeli, Kennedy Mwacalimba, Raymond Tiernan, Erik Mijten, Tetiana Miroshnychenko, Barbara Poulsen Nautrup

    Sheep and goats are an important source of livelihood for smallholder farmers in sub-Saharan Africa (SSA). These livestock are almost entirely managed by resource-poor, smallholder farmers and pastoralists. Despite the large number of sheep and goats in SSA, their productivity is low, mainly due to diseases, poor feed, and inferior breeds. This review aims to summarize the most important diseases in small ruminants in SSA, with a focus on current treatment and control strategies. The following diseases were identified as the most significant constraints for small ruminant farmers: helminthoses, including gastrointestinal nematode infestation, lungworm infestation, fasciolosis, and cerebral coenurosis; viral diseases, such as peste des petits ruminants (PPR), sheep and goat pox, and contagious ecthyma (orf); bacterial diseases, including contagious caprine pleuropneumonia (CCPP), pneumonic pasteurellosis, and anthrax; as well as ectoparasite infestations. The diseases have significant economic implications due to mortality and production losses. Depending on the disease, they may also impact trade and export and hinder the introduction of new, more productive breeds. The ability to control diseases more efficiently is often limited due to financial constraints. In the case of infection with internal parasites, a lack of knowledge about the epidemiology of the disease, as well as the availability of appropriate anthelmintics and the development of resistance against commonly used anthelmintics, are often barriers. The control of viral diseases depends on the accessibility, quality, and handling of vaccines, whereas in bacterial diseases, increasing antibiotic resistance and inappropriate antimicrobial treatments pose challenges, as well as the availability of appropriate vaccines and their use. In the case of ectoparasitic infections, a strategic, regular, and appropriate antiparasitic treatment approach is often not achieved.


  • Open Access

    Diseases of Economic Importance in Feedlot Cattle in Sub-Saharan Africa: A Review with a Focus on Existing and Potential Options for Control

    by Kennedy Mwacalimba, Peter Kimeli, Raymond Tiernan, Erik Mijten, Tetiana Miroshnychenko, Barbara Poulsen Nautrup

    A large number of livestock are found in sub-Saharan Africa (SSA), including 20–25% of the world’s ruminants


  • Open Access

    Renal Disease in Cats and Dogs—Lessons Learned from Text-Mined Trends in Humans

    by Christos Dadousis, Anthony D. Whetton, Kennedy Mwacalimba, Alexandre Merlo, Andrea Wright, Nophar Geifman

    Chronic kidney disease (CKD) is characterised by progressive kidney damage and encompasses a broad range of renal pathologies and aetiologies. In humans, CKD is an increasing global health problem, in particular in the western world, while in cats and dogs, CKD is one of the leading causes of mortality and morbidity. Here, we aimed to develop an enhanced understanding of the knowledge base related to the pathophysiology of renal disease and CKD in cats and dogs. To achieve this, we leveraged a text-mining approach for reviewing trends in the literature and compared the findings to evidence collected from publications related to CKD in humans. Applying a quantitative text-mining technique, we examined data on clinical signs, diseases, clinical and lab methods, cell types, cytokine, and tissue associations (co-occurrences) captured in PubMed biomedical literature. Further, we examined different types of pain within human CKD-related publications, as publications on this topic are sparser in companion animals, but with the growing importance of animal welfare and quality of life, it is an area of interest. Our findings could serve as substance for future research studies. The systematic automated review of relevant literature, along with comparative analysis, has the potential to summarise scientific evidence and trends in a quick, easy, and cost-effective way. Using this approach, we identified targeted and novel areas of investigation for renal disease in cats and dogs.


  • Open Access

    Dog Owners’ Perceptions of the Convenience and Value of Chewable Oclacitinib: Quantitative Survey Data from an International Survey

    by Andrea Wright, Andrew Hillier, Jonathan Lambert, Kennedy Mwacalimba, Natalie Lloyd, Tetsushi Kagiwada, Yoriko Hashiguchi, Carolyne Hours, Danielle Riley, Ashley Enstone, et al.

    Oclacitinib is an oral therapy indicated for pruritus associated with allergic or atopic dermatitis in dogs. This study sought to assess pet owners’ perceptions of the relative convenience and value of the conventional film-coated formulation and the chewable formulation. A quantitative discrete-choice experimental methodology was applied, comparing (conventional, film-coated) oclacitinib versus chewable oclacitinib using unbranded treatment profiles. Initially, a qualitative interview phase with pet owners and veterinarians was conducted to develop detailed treatment profiles. Subsequently, pet owners participated in a quantitative survey. Overall, 1590 pet owners provided survey responses. Most respondents (62%) reported having experienced challenges administering tablet-based therapies to their dog(s). Half of all respondents (52%) had experience administering flavoured or chewable tablets to their dog. Comparing oclacitinib and chewable oclacitinib (with or without associated costs), the majority of the respondents preferred the chewable formulation in all regions across short-term and long-term scenarios (≥58%; all p < 0.05). The current research is one of few survey-driven studies for treatment preferences in companion animal medicine. Veterinarians may offer chewable or palatable treatment options where available, with potential positive impacts on convenience, compliance, outcomes, quality of life, and the human–animal bond.


  • Open Access

    Prevention and long-term outcomes of naturally occurring canine heartworm infection in primary care settings

    by Kennedy Mwacalimba, Jo Ann Morrison, Patrick Ly, Nathaniel Spofford, Mike Yang, Emi Saito, Jenifer Sheehy, Christopher Adolph, Barbara Poulsen Nautrup, Christopher Brennan

    Background: This study had two objectives: first, to examine the association between the history of heartworm preventive purchase compliance and the risk of positive heartworm tests, and second to preliminarily investigate the long-term cardiac outcomes of heartworm disease in dogs that had undergone successful adulticidal therapy.Methods: A retrospective cohort study design was used for both analyses, using anonymous transaction data from Covetrus (retrospective analysis 1) and anonymized medical records from Banfield Pet Hospital (retrospective analysis 2), both including canine patients across the USA. The first analysis examined the relative risk (RR) of a positive heartworm test in dogs with lapses in heartworm preventive purchase history compared to dogs that had no history of a preventive purchase six to 24 months prior to the test. In the second analysis, a long-term evaluation of structured diagnostic codes pertaining to cardiac diseases and risk assessment of outcomes was performed in dogs that had previously been successfully treated for heartworm disease compared to dogs that never had a positive heartworm test.Results: 83,478 unique patients were included in the first analysis. Compared to 32,413 dogs with no history of a heartworm preventive purchase, 44,410 dogs with lapses in monthly preventive purchases had a reduced risk of testing positive for heartworm disease (RR = 0.36, p < 0.0001). Dogs (n = 6,655) with lapses in injectable heartworm preventive administration had a decreased risk of a positive test versus dogs with no preventive purchases (RR = 0.15, p < 0.0001), as well as versus dogs with lapses in monthly heartworm preventive purchases (RR = 0.28, p = 0.0024). In the second analysis, 6,138 patients treated for heartworm infection were found to have significantly (p < 0.001) elevated risks of right heart failure (RR = 3.59), left heart failure (RR = 1.83), or cardiomyopathy (RR = 2.79) compared to 4,022,752 patients that never had a positive heartworm test.Conclusion: This study highlights the importance of compliance with heartworm preventive guidelines, to reduce the risk of heartworm disease in dogs, which is not only a potentially life-threatening condition in the short-term but also associated with long-term negative cardiac outcomes.


  • Open Access

    Diminished antimicrobial drug use in dogs with allergic dermatitis treated with oclacitinib

    by Kennedy Mwacalimba, Andrew Hillier, Michele Rosenbaum, Christopher Brennan, Deborah Amodie

    Introduction: Dogs with allergic dermatitis often suffer concurrent skin and ear infections. The objective of this study was to retrospectively quantify the number of systemic and topical antimicrobial transactions in dogs with allergic dermatitis, following administration of oclacitinib or a glucocorticoid, compared to dogs that did not receive a pruritus therapy when there is an initial diagnosis of pyoderma. A secondary objective was to demonstrate that dogs on oclacitinib use fewer antimicrobials and concomitant therapies over time and have improved quality of life.Materials and methods: This was a retrospective case–control study using a large, centralized database to identify canine patients receiving pruritus therapy along with a concurrent diagnosis of pyoderma. For the second objective, 58 client-owned dogs diagnosed with allergic dermatitis were enrolled in a prospective owner and dog quality of life and treatment satisfaction (QoL&TS) study that also evaluated concomitant therapy use over time. In Part A, data consisted of anonymous transaction records from 1,134 hospitals across the United States, representing pyoderma visits between December 2018 and December 2019. Odds ratios comparing the relative odds of having additional antimicrobial agent transactions were calculated, given initial pruritus therapy compared to dogs that did not receive pruritus therapy. Parametric bootstrapping was used to calculate goodness-of-fit statistics. In part B, dogs entered the study on Day 0 and returned for examination on Days 14, 21, 30, and 60. Owner determination of QoL&TS was performed on Days 0, 1, 3, 14, 21, 30, and 60. On Days 0, 14, 21, and 60, a veterinarian assessed concomitant therapies and dermatitis severity scoring. Least Squares Means and Standard Errors for QoL&TS, and Dermatitis Vet VAS (Visual Analog Scale) Scores were calculated using a Linear Mixed Model Approach for Repeated Measures (α = 0.05). The percent reduction in therapies was also calculated.Results: Dogs that received oclacitinib (n = 5,132) or a glucocorticoid (n = 7,024) had reduced odds (OR: 0.8091; p = 0.0002 and OR: 0.7095; p < 0.0001, respectively) of having a follow up antimicrobial drug transaction after initial antimicrobial therapy compared to dogs with no pruritus therapy at the initial visit (n = 12,997). In part B, oclacitinib demonstrated a statistically significant improvement in QoL&TS scores over time QoL (p < 0.05). Veterinarian assessment showed a 70% reduction in dermatitis severity over time (p < 0.05), supporting oclacitinib’s anti-inflammatory effects. Oclacitinib therapy was also associated with an 83% reduction in concomitant treatments, including a 100% reduction in systemic antimicrobial therapy over eight weeks.Discussion: Dogs receiving oclacitinib showed no increase in antimicrobial therapy transactions compared to glucocorticoid recipients at the initial pyoderma diagnosis. Having a pruritus therapy at the index pyoderma visit reduced the odds of subsequent antimicrobial transactions. In addition to reducing concomitant therapy usage, oclacitinib improved owner and pet QoL, suggesting a paradigm shift in treatment success that could reshape allergic pruritus therapy recommendations. The study provides empirical evidence of oclacitinib’s reduction in antibacterial therapy, supporting its therapeutic value and antimicrobial stewardship.


  • Open Access

    Corrigendum: Retrospective Analysis of Heartworm (Dirofilia immitis) Prevention Medication Compliance and Economic Value in Dogs in Veterinary Practices in Australia

    by Kennedy Mwacalimba, Andrea Wright, Konstantinos Giannakakis, Richard L'EStrange, Tinh-Son Nguyen

    Corrigendum: Retrospective Analysis of Heartworm (Dirofilia immitis) Prevention Medication Compliance and Economic Value in Dogs in Veterinary Practices in Australia